The pharmaceutical company LEO Pharma has sold four pharmaceutical products to the German Cheplapharm for EUR 300m.
The four pharmaceutical products One-Alpha, Locoid, Pimafucin and Zineryt are aimed at dermatology, osteopathy, nephrology, gynaecology etc. In 2019, the pharmaceutical products generated sales of EUR 300m.
The divestment is part of LEO Pharma’s 2030 strategy where the focus on dermatology will make the company a world leader within skin diseases.
The transaction is subject to approval by the authorities and is expected to be completed in December 2020.
Accura advised Leo Pharma in connection with the transaction.
For further information, please read the press release.